Results 251 to 260 of about 299,195 (309)

COVID‐19 and viral hepatitis elimination programs: Are we stepping backward?

Liver international (Print), 2020
As Mendlowitz and colleagues mentioned in a recent commentary, the World Health Organization set a goal for the elimination of viral hepatitis until 2030.
H. Karimi-Sari, M. S. Rezaee-Zavareh
semanticscholar   +1 more source

Vaccines for prevention of viral hepatitis

Haemophilia, 1998
Summary. At the end of the 20th century active immunization against hepatitis A and B has been introduced into routine medical practice. Therefore, patients at risk, and especially those with coagulation disorders, should be immunized at the earliest age possible.
C. A. Lee, C. M. Kessler, D. Varon, U. Martinowitz, M. Heim, D. SHOUVAL   +5 more
openaire   +2 more sources

Viral hepatitis in patients on hemodialysis

Seminars in dialysis, 2020
Hepatitis B and hepatitis C (HCV) prevalence are higher in people on hemodialysis (HD) than the general population. Through implementation of prevention interventions including vaccines, serologic screening, and post‐exposure management, transmissions ...
A. Winston, A. Wurcel, C. Gordon, Nitender Goyal   +3 more
semanticscholar   +1 more source

Viral hepatitis: Global goals for vaccination

Journal of Clinical Virology, 2012
In countries where hepatitis A is highly endemic, exposure to hepatitis A virus (HAV) is almost universal before the age of 10 years, and large-scale immunization efforts are not required. In contrast, in areas of intermediate endemicity or in transition from high to intermediate endemicity, where transmission occurs primarily from person to person in ...
openaire   +2 more sources

Hepatitis B vaccine in hemodialysis patients with hepatitis C viral infection

Vaccine, 1997
Patients on hemodialysis therapy are at a relatively high risk of exposure to hepatitis B virus (HBV) infection. The prevalence of hepatitis C virus (HCV) infection is even higher and was reported as 33.2% in Taiwan. Although the efficacy of hepatitis B vaccine was well documented, the vaccination schedule in hemodialysis patients is not clearly ...
C H, Cheng, C C, Huang, M L, Leu, C Y, Chiang, M S, Wu, P C, Lai   +5 more
openaire   +2 more sources

WITHDRAWN: Viral Hepatitis: global goals for vaccination

Journal of Clinical Virology, 2009
This article has been withdrawn at the request of the author. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
openaire   +2 more sources

Impact of Point-of-Care Testing on Diagnosis, Treatment, and Surveillance of Vaccine-Preventable Viral Infections

Diagnostics
With the advent of a variety of vaccines against viral infections, there are multiple viruses that can be prevented via vaccination. However, breakthrough infections or uncovered strains can still cause vaccine-preventable viral infections (VPVIs ...
Kirthika Lakshmanan, Benjamin M. Liu
semanticscholar   +1 more source

Viral Hepatitis and Diabetes: Clinical Implications of Diabetes Prevention Through Hepatitis Vaccination

Current Diabetes Reports, 2016
Viral hepatitis has been posited to play a role in the development of type 2 diabetes. Thus, prevention of viral hepatitis through vaccination has the potential to reduce the burden of type 2 diabetes. We have shown that successful hepatitis B vaccination reduces the risk of diabetes by 33 %.
Rudruidee, Karnchanasorn, Horng-Yih, Ou, James, Lin, Lee-Ming, Chuang, Ken C, Chiu   +4 more
openaire   +2 more sources

Antigen-Antibody Complex as Therapeutic Vaccine for Viral Hepatitis B

International Reviews of Immunology, 1999
In a previous study, hepatitis B surface antigen (HBsAg) complexed to human anti-HBs immunoglobulins (HBIG) in excess of HBsAg was used as therapeutic vaccine to treat chronic hepatitis B patients and promising results were obtained. To study the mechanisms of this approach, mice were immunized with HBsAg or IC (immunogenic complex, i.e.
Y M, Wen, D, Qu, S H, Zhou
openaire   +2 more sources

An inactivated hepatitis A viral vaccine of cell culture origin

Journal of Medical Virology, 1986
AbstractHepatitis A virus (HAV) strain CR326, adapted to grow in LLC‐MK2 cells, was highly purified, inactivated with formalin, adsorbed to alum, and tested for capacity to induce antibody to HAV in both mice and marmosets. The minimum dose of HAV antigen necessary to produce antibody in 50% of mice was 10 ng.
P J, Provost, J V, Hughes, W J, Miller, P A, Giesa, F S, Banker, E A, Emini   +5 more
openaire   +2 more sources